Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases

• US 20030050268A1
• Filed: 03/29/2002
• Published: 03/13/2003
• Est. Priority Date: 03/29/2001
• Status: Abandoned Application

• Current Assignee: University of Iowa Research Foundation
• Original Assignee: University of Iowa Research Foundation
• Inventors: Krieg, Arthur M., Berg, Daniel J.
• Application Number:
  US10/112,653
• Publication Number:
  US 20030050268A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides methods and compositions for using immunostimulatory nucleic acids to treat non-allergic inflammatory diseases. Non-allergic inflammatory diseases that may be treated according to the methods and products of the invention include psoriasis and inflammatory bowel disease. The invention further provides methods for augmenting a Th1 response to immunostimulatory nucleic acid involving inhibition of prostaglandin-mediated counter-regulatory response.

Claims

1. A method for treating a non-allergic inflammatory disease, comprising:

administering to a subject having or at risk of developing a non-allergic inflammatory disease a therapeutically effective amount of an immunostimulatory nucleic acid to treat or prevent the non-allergic inflammatory disease.

2. The method of claim 1, wherein the therapeutically effective amount of the immunostimulatory nucleic acid reduces or prevents non-allergic inflammation in a tissue of the subject.

3. The method of claim 1, wherein the non-allergic inflammatory disease involves an epithelium.

4. The method of claim 1, wherein the non-allergic inflammatory disease involves a mucosal epithelium.

5. The method of claim 1, wherein the non-allergic inflammatory disease is selected from the group consisting of:

psoriasis, eczema, allergic contact dermatitis, latex dermatitis, and inflammatory bowel disease.

6. The method of claim 1, wherein the non-allergic inflammatory disease is psoriasis.

7. The method of claim 1, wherein the non-allergic inflammatory disease is allergic contact dermatitis.

8. The method of claim 1, wherein the non-allergic inflammatory disease is latex dermatitis.

9. The method of claim 1, wherein the immunostimulatory nucleic acid is a CpG nucleic acid.

10. The method of claim 1, wherein the immunostimulatory nucleic acid is a methylated CpG nucleic acid.

11. The method of claim 1, wherein the immunostimulatory nucleic acid is a T-rich nucleic acid.

12. The method of claim 1, wherein the immunostimulatory nucleic acid is a poly-G nucleic acid.

13. The method of claim 12, wherein the poly-G nucleic acid comprises the formula

5′

-X₁X₂GGGX₃X₄-3′

wherein each of X₁, X₂, X₃, and X₄ is any nucleotide other than G.

14. The method of claim 13, wherein the poly-G nucleic acid does not include any of the formulas 5′

-GXGGG-3′

, 5′

-XGGGG-3′

, or 5′

-GGGXG-3′

, wherein X is any nucleotide.

15. The method of claim 1, wherein the immunostimulatory nucleic acid is a synthetic nucleic acid.

16. The method of claim 1, wherein the immunostimulatory nucleic acid comprises at least one stabilized internucleotide linkage.

17. The method of claim 16, wherein the stabilized internucleotide linkage is a phosphorothioate linkage.

18. The method of claim 1, wherein the immunostimulatory nucleic acid has a backbone completely made up of stabilized internucleotide linkages.

19. The method of claim 1, wherein the immunostimulatory nucleic acid comprises between 6 and 100 nucleotides.

20. The method of claim 1, wherein the immunostimulatory nucleic acid comprises between 8 and 40 nucleotides.

21. The method of claim 1, wherein the immunostimulatory nucleic acid induces IL-12.

22. The method of claim 1, wherein the immunostimulatory nucleic acid induces IFN-α

.

23. The method of claim 1, wherein the immunostimulatory nucleic acid induces IFN-γ

.

24. The method of claim 1, wherein the immunostimulatory nucleic acid induces IL-10.

25. The method of claim 1, wherein the immunostimulatory nucleic acid is administered locally to damaged epithelium.

26. The method of claim 1, wherein the immunostimulatory nucleic acid is administered locally to intact epithelium.

27. The method of claim 1, wherein the immunostimulatory nucleic acid is administered systemically.

28. The method of claim 1, wherein the immunostimulatory nucleic acid is administered orally.

29. The method of claim 1, wherein the immunostimulatory nucleic acid is administered parenterally.

30. The method of claim 1, wherein the immunostimulatory nucleic acid is administered topically.

31. The method of claim 1, wherein the immunostimulatory nucleic acid is administered transdermally.

32. The method of claim 1, further comprising administering to the subject an anti-inflammatory agent selected from the group consisting of:

anti-inflammatory corticosteroids, nonsteroidal anti-inflammatory drugs, vitamin A analogs, vitamin D analogs, retinoids, cytokines, agonists of cytokines, antagonists of cytokines, agonists of cytokine receptors, antagonists of cytokine receptors, cytokine receptor analogs, antibodies specific for cytokines, antibodies specific for cytokine receptors, and immunosuppressive agents.

33. A method for treating inflammatory bowel disease, comprising:

administering to a subject having or at risk of developing an inflammatory bowel disease a therapeutically effective amount of an immunostimulatory nucleic acid to treat or prevent the inflammatory bowel disease.

34. The method of claim 33, wherein the inflammatory bowel disease is ulcerative colitis.

35. The method of claim 33, wherein the inflammatory bowel disease is Crohn'"'"'s disease.

36. The method of claim 33, wherein the immunostimulatory nucleic acid is a CpG nucleic acid.

37. The method of claim 33, wherein the immunostimulatory nucleic acid is a methylated CpG nucleic acid.

38. The method of claim 33, wherein the immunostimulatory nucleic acid is a T-rich nucleic acid.

39. The method of claim 33, wherein the immunostimulatory nucleic acid is a poly-G nucleic acid.

40. The method of claim 39, wherein the poly-G nucleic acid comprises the formula

5′

-X₁X₂GGGX₃X₄-3′

wherein each of X₁, X₂, X₃, and X₄ is any nucleotide other than G.

41. The method of claim 40, wherein the poly-G nucleic acid does not include any of the formulas 5′

-GXGGG-3′

, 5′

-XGGGG-3′

, or 5′

-GGGXG-3′

, wherein X is any nucleotide.

42. The method of claim 33, wherein the immunostimulatory nucleic acid is a synthetic nucleic acid.

43. The method of claim 33, wherein the immunostimulatory nucleic acid comprises at least one stabilized internucleotide linkage.

44. The method of claim 43, wherein the stabilized internucleotide linkage is a phosphorothioate linkage.

45. The method of claim 33, wherein the immunostimulatory nucleic acid has a backbone completely made up of stabilized internucleotide linkages.

46. The method of claim 33, wherein the immunostimulatory nucleic acid comprises between 6 and 100 nucleotides.

47. The method of claim 33, wherein the immunostimulatory nucleic acid comprises between 8 and 40 nucleotides.

48. The method of claim 33, wherein the immunostimulatory nucleic acid induces IL-12.

49. The method of claim 33, wherein the immunostimulatory nucleic acid induces IFN-α

.

50. The method of claim 33, wherein the immunostimulatory nucleic acid induces IFN-γ

.

51. The method of claim 33, wherein the immunostimulatory nucleic acid induces IL-10.

52. The method of claim 33, wherein the immunostimulatory nucleic acid is administered locally to damaged mucosal epithelium.

53. The method of claim 33, wherein the immunostimulatory nucleic acid is administered locally to intact mucosal epithelium.

54. The method of claim 33, wherein the immunostimulatory nucleic acid is administered systemically.

55. The method of claim 33, wherein the immunostimulatory nucleic acid is administered orally.

56. The method of claim 33, wherein the immunostimulatory nucleic acid is administered rectally.

57. The method of claim 33, wherein the composition is administered parenterally.

58. The method of claim 33, further comprising administering to the subject an anti-inflammatory agent selected from the group consisting of:

5-aminosalicylate, agents containing 5-aminosalicylate, anti-inflammatory corticosteroids, nonsteroidal anti-inflammatory drugs, cytokines, agonists of cytokines, antagonists of cytokines, agonists of cytokine receptors, antagonists of cytokine receptors, cytokine receptor analogs, antibodies specific for cytokines, antibodies specific for cytokine receptors, and immunosuppressive agents.

59. The method of claim 33, further comprising administering to the subject an anti-inflammatory agent selected from the group consisting of:

5-aminosalicylate and agents containing 5-aminosalicylate.

60. A pharmaceutical composition, comprising:

an immunostimulatory nucleic acid in an effective amount for preventing or treating an immune or inflammatory response associated with a non-allergic inflammatory disease,

a non-allergic inflammatory disease medicament, and

a pharmaceutically acceptable carrier.

61. The pharmaceutical composition of claim 60, wherein the non-allergic inflammatory disease is selected from the group consisting of:

psoriasis, eczema, allergic contact dermatitis, latex dermatitis, and inflammatory bowel disease.

62. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid is a CpG nucleic acid.

63. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid is a methylated CpG nucleic acid.

64. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid is a T-rich nucleic acid.

65. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid is a poly-G nucleic acid.

66. The pharmaceutical composition of claim 65, wherein the poly-G nucleic acid comprises the formula

5′

-X₁X₂GGGX₃X₄-3′

wherein each of X₁, X₂, X₃, and X₄ is any nucleotide other than G.

67. The pharmaceutical composition of claim 66, wherein the poly-G nucleic acid does not include any of the formulas 5′

-GXGGG-3′

, 5′

-XGGGG-3′

, or 5′

-GGGXG-3′

, wherein X is any nucleotide.

68. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid is a synthetic nucleic acid.

69. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid comprises at least one stabilized internucleotide linkage.

70. The pharmaceutical composition of claim 69, wherein the stabilized internucleotide linkage is a phosphorothioate linkage.

71. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid has a backbone completely made up of stabilized internucleotide linkages.

72. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid comprises between 6 and 100 nucleotides.

73. The pharmaceutical composition of claim 60, wherein the immunostimulatory nucleic acid comprises between 8 and 40 nucleotides.

74. The pharmaceutical composition of claim 60, wherein the non-allergic inflammatory disease medicament is selected from the group consisting of:

5-aminosalicylate, agents containing 5-aminosalicylate, anti-inflammatory corticosteroids, nonsteroidal anti-inflammatory drugs, vitamin A analogs, vitamin D analogs, retinoids, cytokines, agonists of cytokines, antagonists of cytokines, agonists of cytokine receptors, antagonists of cytokine receptors, cytokine receptor analogs, antibodies specific for cytokines, antibodies specific for cytokine receptors, and immunosuppressive agents.

75. A pharmaceutical composition, comprising:

an immunostimulatory nucleic acid in an effective amount for preventing or treating an immune or inflammatory response associated with a non-allergic inflammatory disease, and

a pharmaceutically acceptable carrier, wherein the immunostimulatory nucleic acid and pharmaceutically acceptable carrier are prepared in a formulation selected from the group consisting of;

a lotion, a cream, an ointment, and a gel.

76. The pharmaceutical composition of claim 75, wherein the non-allergic inflammatory disease is selected from the group consisting of:

psoriasis, eczema, allergic contact dermatitis, and latex dermatitis.

77. The pharmaceutical composition of claim 75, wherein the non-allergic inflammatory disease is psoriasis.

78. The pharmaceutical composition of claim 75, wherein the non-allergic inflammatory disease is allergic contact dermatitis.

79. The pharmaceutical composition of claim 75, wherein the non-allergic inflammatory disease is latex dermatitis.

80. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid is a CpG nucleic acid.

81. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid is a methylated CpG nucleic acid.

82. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid is a T-rich nucleic acid.

83. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid is a poly-G nucleic acid.

84. The pharmaceutical composition of claim 83, wherein the poly-G nucleic acid comprises the formula

5′

-X₁X₂GGGX₃X₄-3′

wherein each of X₁, X₂, X₃, and X₄ is any nucleotide other than G.

85. The pharmaceutical composition of claim 84, wherein the poly-G nucleic acid does not include any of the formulas 5′

-GXGGG-3′

, 5′

-XGGGG-3′

, or 5′

-GGGXG-3′

, wherein X is any nucleotide.

86. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid is a synthetic nucleic acid.

87. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid comprises at least one stabilized internucleotide linkage.

88. The pharmaceutical composition of claim 87, wherein the stabilized internucleotide linkage is a phosphorothioate linkage.

89. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid has a backbone completely made up of stabilized internucleotide linkages.

90. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid comprises between 6 and 100 nucleotides.

91. The pharmaceutical composition of claim 75, wherein the immunostimulatory nucleic acid comprises between 8 and 40 nucleotides.

92. A method of augmenting Th1-like immune activation induced by an immunostimulatory nucleic acid, comprising:

contacting an immune cell with an effective amount of an immunostimulatory nucleic acid to induce Th1-like immune activation; and

contacting the immune cell with an inhibitor of cyclooxygenase-2 (COX-2) expression, in an amount effective to augment Th1-like immune activation induced by the immunostimulatory nucleic acid.

93. The method of claim 92, wherein the immunostimulatory nucleic acid is administered to a subject in need of Th1-like immune activation in an effective amount to induce Th1-like immune activation, and wherein the inhibitor of COX-2 expression is administered to the subject in an effective amount to augment Th1-like immune activation induced by the immunostimulatory nucleic acid.

94. A method of augmenting Th1-like immune activation induced by an immunostimulatory nucleic acid, comprising:

contacting an immune cell with an effective amount of an immunostimulatory nucleic acid to induce Th1-like immune activation; and

contacting the immune cell with an agent that inhibits PGE₂ signaling through its receptor, in an amount effective to augment the Th1-like immune activation induced by the immunostimulatory nucleic acid.

95. The method of claim 94, wherein the agent that inhibits PGE₂ signaling through its receptor is an antibody that binds specifically to PGE₂.

96. The method of claim 94, wherein the immunostimulatory nucleic acid is administered to a subject in need of Th1-like immune activation in an effective amount to induce Th1-like immune activation, and wherein the agent that inhibits PGE₂ signaling through its receptor is administered to the subject in an effective amount to augment the Th1-like immune activation.

97. A method of augmenting Th1-like immune activation in a subject, comprising:

administering to a subject in need of Th1-like immune activation an effective amount of an immunostimulatory nucleic acid to induce Th1-like immune activation; and

administering to the subject an effective amount of a cyclooxygenase inhibitor to inhibit prostaglandin expression, wherein the subject is free of symptoms of asthma or allergy otherwise calling for treatment with immunostimulatory nucleic acid, and wherein Th1-like immune activation induced by administering the immunostimulatory nucleic acid and the cyclooxygenase inhibitor is greater than Th1-like immune activation induced by administering the immunostimulatory nucleic acid alone.

98. The method of claim 97, wherein the prostaglandin is PGE₂.

99. The method of claim 97, wherein the cyclooxygenase inhibitor is a nonsteroidal anti-inflammatory drug (NSAID).

100. The method of claim 97, wherein the cyclooxygenase inhibitor is a selective inhibitor of COX-2 catalytic activity.